Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 17:25 ET | Source: Muscular Dystrophy Association

FDA Approves KYGEVVI® (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 deficiency (TK2d), a Rare and Devastating Mitochondrial Disease

New York, Nov. 03, 2025 (GLOBE NEWSWIRE) -- New York, Monday, November 3, 2025 – The Muscular Dystrophy Association (MDA) marks another milestone today in our legacy of progress with the FDA...
October 28, 2025 07:00 ET | Source: Sitryx Therapeutics

Sitryx presents new preclinical data highlighting MTHFD2 as a novel metabolic target in autoimmune disease at ACR Convergence 2025

Preclinical data highlight MTHFD2 as a promising metabolic target in autoimmune disease, providing strong validation for the advancement of SIT-047, Sitryx’s MTHFD2 inhibitor program, into clinical...
October 15, 2025 07:00 ET | Source: Sitryx Therapeutics

Sitryx to participate in upcoming investor conferences

Oxford, UK and Boston, MA – October 15, 2025 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune...
October 08, 2025 07:09 ET | Source: Nilo Therapeutics

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer

Nilo Therapeutics launches with $101 million Series A to target neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer
October 02, 2025 07:00 ET | Source: Sitryx Therapeutics

Sitryx receives FDA clearance of IND application for SYX-5219 for the treatment of atopic dermatitis

SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease remission across a range of autoimmune diseasesPhase 1b trial to investigate the safety, tolerability and initial...
October 02, 2025 06:30 ET | Source: Custom Market Insights

[Latest] Global Virtual Clinical Trials Market Size/Share Worth USD 15.8 Billion by 2034 at a 5.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Virtual Clinical Trials Market Size, Trends and Insights By Study Design...
October 01, 2025 09:20 ET | Source: Palisade Bio, Inc.

Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock

Carlsbad, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel...
September 25, 2025 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today...
August 25, 2025 09:00 ET | Source: Palisade Bio, Inc.

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

– Moderated discussion with leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan – Segment provides further insight into the need for more...
August 08, 2025 12:00 ET | Source: Sitryx Therapeutics

Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization

Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization Novel, oral candidate with first-in-class...